AMPY vs CRC: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CRC is the larger of the two ($3.94B market cap): the incumbent the market prices for continued execution (14.34x forward earnings, beta 0.95). AMPY is the smaller challenger ($155.01M), cheaper on forward earnings (4.61x): more room to run, but more to prove. On the numbers, AMPY leads on both counts: faster expected revenue growth (12% vs -5%) and a lower forward P/E (4.61x vs 14.34x). The case for CRC rests on its own driver (A Brent-linked barrel in a high oil price year): if you believe in that, CRC fits; if you believe in what the numbers show today, AMPY does.

AMPY vs CRC: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAMPYCRCWhat it tells you
Market cap$155.01M$3.94BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E4.6114.34Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.250.95Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range20% of range5% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book0.381.30How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: AMPY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how AMPY and CRC affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMPY and CRC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMPY and CRC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Amplify Energy (AMPY) do?

Amplify Energy Corp. is a Houston-based independent oil producer listed on the NYSE. Until late 2025 it ran a mixed portfolio spanning East Texas and Louisiana gas, Oklahoma, the Eagle Ford and two oil assets. Over 2025 it closed six transactions worth about $250M, including the $122M East Texas sale and the $92.5M Oklahoma sale in December, and used the proceeds to repay its entire credit facility. What remains is Beta, a set of platforms in federal waters off Huntington Beach, California, and Bairoil, a carbon dioxide enhanced oil recovery (EOR) unit in Wyoming. Production is now ~7.4 thousand barrels a day and 100% oil (Q3 2026), down from ~18.4 MBoe/d across the old portfolio in 2025.

Full AMPY guide

What does California Resources Corporation (CRC) do?

California Resources was spun out of Occidental Petroleum in 2014 and operates from Long Beach with about 2,500 employees. It produces crude oil, natural gas liquids and natural gas from the San Joaquin, Los Angeles and Sacramento basins in California, plus the Uinta basin in Utah, and it sells almost all of that output into California refineries. Proved reserves stood at about 654 million barrels of oil equivalent at the end of 2025, roughly 83% of it oil, concentrated in long-life conventional fields like Belridge and Elk Hills where decline rates are low and steamflood and waterflood techniques do most of the work. The company also owns gas-fired power generation that supplies its own field operations, and it runs a second reporting segment, Carbon TerraVault, which builds CO2 capture equipment and injects CO2 into depleted reservoirs. Its structural advantage is location: California imports more than 75% of the oil it consumes, so CRC's barrels price off Brent with a transportation-cost edge over waterborne imports into refineries already configured for California-style crude. On December 18, 2025 CRC closed an all-stock combination with Berry Corporation, issuing about 5.6 million shares at an exchange ratio of 0.0718, which left former Berry holders owning roughly 6% of the company and added the Utah acreage.

Full CRC guide

AMPY vs CRC: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • AMPY drivers: Beta drilling in the Joulters fault block; Royalty relief and lower operating costs.
  • CRC drivers: A Brent-linked barrel in a high oil price year; SB 237 reopening Kern County drilling.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Amplify is now a two-asset company, so a single operational problem can swing results. For CRC, the hedge book is the most immediate distortion: CRC gave up about $15 a barrel to derivative settlements in the second quarter of 2026 ($76.50 realized after settlements versus $91.64 before), and the non-cash mark on those contracts produced a $711 million GAAP loss in the first quarter, so trailing earnings multiples are close to meaningless right now.

AMPY or CRC: which should you pick?

If the story you believe is AMPY's (Beta drilling in the Joulters fault block), AMPY is the more direct way to own it; if it is CRC's (A Brent-linked barrel in a high oil price year), CRC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMPY and CRC guides.

AMPY vs CRC: the full fundamentals

AMPY. Headline multiples flatter and confuse in equal measure. The trailing P/E of ~6.6 rests on gains from asset sales and derivatives, and trailing revenue of ~$198M still includes December 2025 output from East Texas and Oklahoma; the continuing business generated ~$141M of revenue in the first nine months of 2026. With no revolver debt and ~$10M of cash at September 30, enterprise value is roughly ~$150M, or about 4x to 5x guided 2026 EBITDA, and the market cap is well under half of proved PV-10. Adding ~$72M of retirement obligations narrows that gap. The two-analyst consensus target sits near ~$7.75.

CRC. Trailing GAAP numbers still mislead: derivative losses in the first and third quarters leave trailing EPS near -$5.60, so the forward P/E near 14 times and cash-flow measures do more work, with operating cash flow of about $902 million and free cash flow near $312 million over the trailing year. Enterprise value near 117 times trailing EBITDA looks extreme only because reported EBITDA carries the hedge marks. Analysts remain positive, with a strong-buy consensus and a mean target near $74, well above the November 20, 2026 close after an 18% one-month slide.

Headline figures (approximate, November 2026): AMPY shows share price (nov. 20, 2026) $3.84, market cap ~$154M, revenue (ttm) ~$198M (includes assets sold in Dec 2025), net income (ttm) ~$22M (swung by hedge marks and asset-sale gains); CRC shows revenue (ttm) ~$3.95B, up ~25% YoY in Q3 2026; GAAP figures include derivative marks, q3 2026 earnings ~$315M GAAP net loss; adjusted EPS ~$1.17 vs ~$0.98 consensus, net income (ttm) ~-$500M, after derivative-driven losses in Q1 and Q3 2026, adjusted ebitdax $341M in Q3 2026; 2026 guide ~$1.34B at $92 Brent.

The bottom line: AMPY vs CRC

AMPY and CRC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AMPY and CRC exposure against your real portfolio. It is not an investment adviser.

Wondering how AMPY or CRC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Amplify Energy

Ask Walnut's AI anything about AMPY and see how it fits what you own.

FAQ

What is the difference between AMPY and CRC?

+

Amplify Energy Corp. California Resources was spun out of Occidental Petroleum in 2014 and operates from Long Beach with about 2,500 employees. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AMPY or CRC the better stock?

+

Neither is universally better. CRC is the larger incumbent; AMPY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AMPY or CRC?

+

On forward P/E (as of November 2026), AMPY trades at 4.61x and CRC at 14.34x, so AMPY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AMPY and CRC?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AMPY vs CRC?

+

AMPY: Amplify is now a two-asset company, so a single operational problem can swing results. Beta runs on platforms installed decades ago and a pipeline to shore; in October 2021 that pipeline leaked ~25,000 gallons of crude off Huntington Beach, shutting the field until 2023 and producing criminal and civil settlements. Another incident would carry heavy financial and reputational cost, and California remains hostile to offshore oil, with permitting, litigation and political risk well above Texas norms. Decommissioning obligations are large: asset retirement obligations were ~$72M at year end 2025 and the company funds a Beta sinking fund of ~$9M a year. Free cash flow was negative in the first half of 2026 and only ~$2.0M in Q3, and liquidity was a modest ~$25M at September 30 (~$10M of cash plus ~$15M of revolver capacity), with a borrowing base redetermination underway. Hedges mean a price spike helps less than the headline suggests, and swings in their mark-to-market value drive large GAAP losses, as Q3's ~$24.6M unrealized loss showed; a price collapse after Middle East supply normalizes would hurt high-cost barrels quickly. Pump failures cut Beta output in the first half. Analyst coverage is thin, trading volume is light, and the 2025 Juniper merger that was announced and then terminated shows how strategic plans here can change abruptly. CRC: The hedge book is the most immediate distortion: CRC gave up about $15 a barrel to derivative settlements in the second quarter of 2026 ($76.50 realized after settlements versus $91.64 before), and the non-cash mark on those contracts produced a $711 million GAAP loss in the first quarter, so trailing earnings multiples are close to meaningless right now. Everything else runs on the oil price, which the company does not control and which cuts both ways. California is a uniquely hostile operating jurisdiction: CalGEM has prohibited well stimulation treatments, is running a five-year injection pressure reduction plan at the Wilmington field with the next phase on hold until fall 2026, and local ordinances continue to layer setbacks and restrictions on drilling. Refinery closures and declining in-state demand are a structural headwind to the customer base, and asset retirement obligations of about $906 million are a real long-dated liability for a producer with decades-old wells. The dividend and the repurchase program are both discretionary and priced off commodity cash flow, so a sustained oil downturn would pressure returns of capital, the roughly $1.35 billion debt load and the Berry integration at the same time. The November 2026 court ruling against the CTV I environmental review adds legal risk to the carbon business, and the power and data center plans are at the memorandum stage with no binding contracts.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMPY or CRC; figures are approximate and dated (as of November 2026). Verify current data before investing.